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Correction/Clariﬁ  cation about FDA 
Review Documents 
Erick Turner 
Emma Veitch cites my PLoS Medicine Essay [1] about how 
the Food and Drug Administration’s (FDA’s) review of 
documents can serve as a source of clinical trials data, but 
she follows it up with the statement, “However, it is difﬁ  cult 
to have conﬁ  dence in data released by sponsors when the 
data have not been subjected to external, independent peer 
review. Furthermore, this information is not integrated with 
other data, or indexed” [2].
While I agree with the second assertion, the ﬁ  rst 
assertion—that the data are not subjected to external, 
independent peer review—is off the mark. FDA reviews are 
indeed external and independent to the sponsor. These 
reviews are conducted not by the sponsors but by physicians 
and scientists employed by the United States government. 
True, the data originate with the sponsor. However, once the 
sponsor submits data to the FDA, a level of rigor and scrutiny 
is applied to them that is arguably higher than what occurs in 
the typical journal manuscript review process. 
First, FDA reviewers typically revisit the original protocol 
submitted before the study was conducted in order to verify 
that the sponsor has not engaged in hypothesizing after the 
results are known (“HARKing”) [3]. By contrast, journal 
reviewers typically do not have access to the original protocol. 
As a result, they must trust that HARKing has not occurred, a 
dubious assumption in view of recent data [4]. 
Second, FDA statistical reviewers obtain the raw data 
from the sponsor, and determine whether the sponsor’s 
ﬁ  ndings can be replicated. By contrast, journal reviewers 
typically have access to only the summary statistics reported 
(perhaps selectively) to them by the authors or the sponsors. 
Consequently, reviewers can only speculate whether they 
could replicate the ﬁ  ndings. 
As a result, I believe that the FDA review process warrants 
a higher level of conﬁ  dence than the conventional journal 
manuscript review process.  
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Editor’s Reply
Erick Turner appropriately points out the high levels of 
rigor applied during regulatory authorities’ review of 
clinical trial data [1]. However, the statement beginning 
“However, it is difﬁ  cult to have conﬁ  dence in data released 
by sponsors...” [2] was not intended to highlight the release 
of review documents by the Food and Drug Administration 
(FDA), but rather the publication of summary clinical trial 
data on sponsors’ own Web sites, which does seem to lack 
an integral peer-review mechanism. I support efforts to 
make Drugs@FDA more systematic and comprehensive, an 
initiative which can sit comfortably alongside peer-reviewed 
journal publication.  
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The Statistical Signiﬁ  cance of Suffering
Kristen Suthers
Musa Mayer makes several good points about the importance 
of enrolling people with life-threatening conditions in clinical 
trials in order to identify new treatments and speed the 
pipeline along for the greater good [1]. However, the idea that 
clinical trial enrollment suffers when seriously ill individuals 
are provided compassionate use of treatments is myopic; one 
does not negate the other. In many cases, persons who seek 
compassionate use of medications are ineligible for the clinical 
trials Mayer would want them to enroll in, and will likely die 
or suffer considerably before the experimental treatment they 
are seeking is approved for the public. In a world of limited 
resources, we need to ask, how do we encourage enrollment 
in clinical trials to develop treatments and cures that will 
beneﬁ  t people in the future, while humanely treating those 
who are ineligible for these trials and suffer right now? The 
ﬁ  rst step is to understand that clinical trial enrollment and 
compassionate-use programs are not competing interests 
today, as they perhaps were in the 1980s and 1990s. The next 
step is to educate the public, not only about the importance 
of enrollment in clinical trials, but about their rights as 
informed participants in the noble process of science. Mayer’s 
perspective [1] fails to consider the ultimate goal of clinical 
trials: to relieve human suffering. It serves no one’s interest to 
demand an all-or-nothing approach to scientiﬁ  c progress. As 
Einstein said, “Not everything that can be counted counts, and 
not everything that counts can be counted.”  
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Controlling the Spread of HIV/AIDS in 
the Indian Subcontinent
Govindasamy Agoramoorthy, Minna J. Hsu
The article on HIV/AIDS infection by Singh and colleagues 
outlines an alarming fact about the spread of this deadly 
virus in Nepal [1]. We would like to add that more assertive 
campaigns are necessary to curb the spread of infection 
in the Indian subcontinent before it’s too late. In the year 
2000 alone, a total of 5.3 million people were infected with 
HIV worldwide [2]. Since the epidemic started two decades 
ago, HIV/AIDS has killed 22 million people globally. India, 
Indochina, and the former Soviet republics have seen the most 
rapid rise of HIV incidence in recent years. AIDS experts have 
raised alarm bells over its spread in the Asia-Paciﬁ  c region, 
and called for a united effort to control it. The Joint United 
Nations Programme on HIV/AIDS (UNAIDS) estimates about 
5 million people in India alone are infected.
The ﬁ  rst report of HIV/AIDS infection in India was in 
1986, and since then the virus has spread rapidly throughout 
the country. Both HIV serotypes 1 and 2 exist in India, and 
HIV-1 C is the most common subtype reported. Sexual 
transmission of HIV is the predominant route of transmission 
in India [3]. According to the Ministry of Health in New 
Delhi, only 3% of Indians use condoms for birth control, 
since the tradition and culture dictate that women undergo 
sterilization or take birth control pills. Prostitution plays a 
major role in spreading the disease among the heterosexuals 
in urban areas. Although Mumbai appears to be the main 
locus for AIDS, rapid spread has occurred through other 
major cities as well. Migration of people from cities to rural 
areas is so rapid that the disease may already be out of control 
in many areas. The blood screening tests conducted at most 
hospitals in rural India are not adequate to conﬁ  rm presence 
of the virus, making blood transfusion unsafe. The National 
AIDS Control Organization (NACO), the apex body for 
controlling AIDS in India, has reported a high incidence 
(8.2%) of blood donors who are HIV-positive among healthy 
blood donors in urban areas [4].
AIDS is a sexually transmitted disease, and as long as 
people are educated thoroughly and warned about the 
dangerous consequences of unsafe sex, there is less to fear. 
Unfortunately, the intervention program launched by the 
NACO had very little impact in controlling the spread 
of the epidemic in India [4]. The current educational 
programs are often restricted to the passive dissemination of 
information through posters, media, and display of safe-sex 
billboards behind automobiles. More aggressive efforts are, 
therefore, needed to reach out to each and every rural/urban 
community throughout India to combat the spread of the 
disease. The state and central government agencies must 
build specialized shelters for people with HIV/AIDS. More 
funds must be spent for effective AIDS awareness campaigns, 
research, routine screening tests, and treatment.
According to the Asia Paciﬁ  c Network of People Living with 
AIDS, a considerable number of people were refused treatment 
or delayed provision of treatment or health services after 
being diagnosed with HIV/AIDS. Breaches of conﬁ  dentiality 
by health workers were common in Asian countries. Within 
families and communities, women were discriminated against 
more than men—including ridicule, harassment, and physical 
assault—and they were often forced to change their place of 
residence because of their HIV status [5].
Although politicians and policymakers are increasingly 
committed to AIDS prevention and control efforts in 
countries such as India, a multidisciplinary approach such 
as early identiﬁ  cation and treatment of sexually transmitted 
diseases, promotion of condom usage, rapid blood screening 
to test for HIV in rural areas, public awareness campaigns, 
poverty eradication, and development of prevention 
interventions have to be considered for effective control of 
the spread of this virus in the Indian subcontinent. 
Moreover, people from all walks of life must take an active 
role to promote AIDS awreness and prevention across the 
Indian subcontinent. It is time for the local and regional 
celebrities, such as political leaders, movie stars, and beauty 
pageant winners, in the Indian subcontinent to get involved 
in helping people with HIV and in educating the public, 
which would certainly raise awareness among the rural public 
more quickly than current efforts. It is time to remember how 
the late Princess of Wales reached out to people with AIDS, 
shook hands to console them, and also raised millions of 
dollars for their welfare. Countries in the Indian subcontinent 
have experienced and handled the outbreak of deadly 
epidemics in the past [6], and we hope that AIDS can also be 
controlled and eradicated eventually in the near future.  
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